Experimental Drug Setanaxib Shows Promise in Safeguarding Hearts of Duchenne Patients

Experimental drug Setanaxib shows promise for preserving cardiac health in Duchenne muscular dystrophy

A recent study published in Molecular Therapy reports that the investigational compound Setanaxib can protect heart function in preclinical models of Duchenne muscular dystrophy (DMD). Researchers observed maintained cardiac output, reduced heart enlargement, and less tissue scarring after treatment.

Key findings point to NOX4 as a therapeutic target

“The results are very promising.”

The work highlights the enzyme NOX4, which drives oxidative stress, as a potential focus for future cardiomyopathy therapies linked to DMD.

Study led by USF Health investigators

Da‑Zhi Wang, a professor at the University of South Florida Health Morsani College of Medicine and director of the Center for Regenerative Medicine at the USF Health Heart Institute, spearheaded the research. Collaborators included John Mably, associate professor, Gabriela Diniz, assistant professor, and external partners.

Wang noted, “Despite great progress in gene‑replacement approaches, Duchenne muscular dystrophy remains a devastating disease. Understanding the mechanisms that drive disease progression is essential for developing therapies that improve quality of life.”

Background on Duchenne muscular dystrophy and cardiac risk

DMD, an X‑linked disorder, primarily affects boys and is caused by mutations that eliminate functional dystrophin, a protein that stabilizes muscle cells. Without dystrophin, repeated contractions damage muscle fibers, leading to replacement by fat and scar tissue. The heart, which must contract continuously, is especially susceptible; progressive damage can cause enlargement, reduced pumping efficiency, and eventual heart failure.

Advances in supportive care have extended life expectancy for individuals with DMD, making cardiac protection an increasingly critical component of disease management.

Setanaxib’s mechanism and impact on heart tissue

Setanaxib targets the enzymes NOX1 and NOX4, which generate reactive oxygen species. While these molecules serve normal signaling roles at low concentrations, excess production fuels inflammation and fibrosis. In the study, Setanaxib reduced oxidative stress, lowered inflammatory markers, and decreased expression of genes associated with cardiomyopathy, thereby preserving the heart’s pumping ability.

Implications for clinical development

John Mably emphasized, “The Nox4 inhibitor has already undergone clinical trials for lung fibrosis and kidney and liver disease. We hope it will soon be evaluated in DMD patients to slow heart disease progression.”

Gabriela Diniz added, “Our findings demonstrate how basic biomedical research drives advances in human health and underscores the value of our cardiac and regenerative medicine program.”